Replies to post #1491 on Idera Pharmaceuticals Inc (IDRA)

[jimmybob]

Idera reports third dose cohort in ongoing WM trial opened for enrollment
Idera is currently conducting a Phase 1/2 clinical trial of IMO-8400 in patients with Waldenström's macroglobulinemia, or WM, who have a history of relapse or failure to respond to one or more prior therapies. The objectives of the trial are to evaluate the compound's safety, tolerability and potential clinical activity. The protocol includes three dose-escalation cohorts of IMO-8400 administered subcutaneously. The trial's independent data review committee has completed its review of four-week safety data from the second dose cohort and has determined that Idera may open enrollment in the third dose cohort. Final 24-week safety and clinical activity data are anticipated in the second half of 2015